Numerous clinical trials are always open and enrolling patients in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults 18 years of age and older who have or are at risk of developing cancer. The table below contains a list of all active clinical trials, with links to the educational and recruitment materials that are publicly available to patients and researchers.
The trials below are listed alphabetically by cancer type. To sort, hover over any of the column headings and click the up/down arrows. You can also search by keyword. To access the educational and recruitment material for a particular trial, click on the trial ID.
| Cancer Type | Target Patient Population | Trial ID/Educational Material |
|---|---|---|
| Various | Metastatic (advanced) solid tumors, lymphomas, or myeloma and also rare cancer types with no standard treatment available | EAY131 / NCI-MATCH |
| Any | Ages 18-39 with any type of cancer except basal cell carcinoma | EAQ202 |
| Any | Current smokers wanting to stop | EAQ171CD |
| Any | Cancer patients with pneumonitis (lung inflammation) | EAQ172 |
| Anus | Metastatic (advanced), not able to be removed by surgery (inoperable) | EA2176 |
| Anus | Squamous cell type, no prior treatment | EA2182 / DECREASE |
| Bile Duct | Metastatic (advanced) cholangiocarcinoma | EA2187 |
| Blood | Acute lymphoblastic leukemia (ALL) | EA9152 |
| Blood | Acute lymphoblastic leukemia (ALL) | EA9181 |
| Blood | Chronic myeloid leukemia (CML) | EA9171 / BLAST MRD CML 1 |
| Blood | Hodgkin lymphoma | E4412 |
| Blood | Mantle cell lymphoma | EA4151 |
| Blood | Mantle cell lymphoma | EA4181 |
| Blood | Myeloma, newly diagnosed | EAA181 / EQUATE |
| Blood | Smoldering myeloma | EAA173 / DETER-SMM |
| Blood | Previously diagnosed with multiple myeloma and on lenalidomide | EAA171 / OPTIMUM |
| Blood | Suspected myelodysplastic syndromes | NHLBI-MDS / The National MDS Study |
| Bladder | Spread to lymph nodes | EA8185 / INSPIRE |
| Brain | Recurrent glioblastoma | EAF151 |
| Breast | Women planning for regular mammograms | EA1151 / TMIST |
| Breast | HER2 positive type | EA1181 / CompassHER2 pCR |
| Breast | Metastatic (advanced) with bone or mostly bone disease | EA1183 / FEATURE |
| Breast | Newly diagnosed, metastatic (advanced) | EAI142 |
| Breast | Black women with breast cancer | EAZ171 |
| Breast | Women who decline the TMIST breast cancer screening trial | EAQ201 |
| Esophagus | Locally advanced, able to be removed by surgery (operable) | EA2174 |
| Esophagus and Stomach | Metastatic (advanced), HER2 negative type | EA2183 |
| Gallbladder | Discovered at time of surgery to remove the gallbladder | EA2197 / OPT-IN |
| Head and Neck | p53-mutated squamous cell type, after surgery | EA3132 |
| Head and Neck | Squamous cell type, able to be removed by surgery (operable) | EA3191 |
| Head and Neck | Metastatic (advanced) squamous cell type that has returned after treatment with immune checkpoint inhibitors | EA3202 |
| Kidney or Thyroid | Blood pressure management | EAQ191 / CARISMA |
| Lung | Non-small cell type, metastatic (advanced) | EA5162 |
| Lung | Non-small cell type, metastatic (advanced) | EA5163 / S1709 / INSIGNA |
| Lung | Non-small cell type, not able to be removed by surgery (inoperable) | EA5181 |
| Lung | Non-small cell type, metastatic (advanced) | EA5182 |
| Lung | Non-small cell, non-squamous type | EA5191 |
| Lung | Non-small cell type, able to be removed by surgery (operable) | E4512, an ALCHEMIST Trial |
| Nose and Sinus | Squamous cell, HPV positive type | EA3163 |
| Pancreas | Patients with non-cancerous pancreas cysts | EA2185 |
| Pancreas | Metastatic (advanced), older (aged 70+) | EA2186 / GIANT |
| Pancreas | After surgery and BRCA1, BRCA2, or PALB2 type | EA2192 / APOLLO |
| Penis | Metastatic (advanced) | EA8134 / InPACT |
| Prostate | Newly diagnosed, before surgery | EA8171 |
| Prostate | Within 6 weeks of surgery (radical prostatectomy) and at highest risk of progression to metastatic (advanced) stage | EA8183 / ERADICATE |
| Prostate | On active surveillance, with very low, low, or favorable intermediate risk of progressing | EA8184 |
| Prostate | Rise in PSA after surgery (radical prostatectomy) | EA8191 / INDICATE |
| Rectum | Locally advanced, MSI-high or dMMR type | EA2201 |
| Skin | Melanoma, metastatic (advanced) | EA6141 |
| Skin | Melanoma, Merkel cell type | EA6174 / STAMP |
| Skin | Melanoma, cutaneous or unknown primary type | EA6183 |
| Skin | Melanoma, locally advanced, not able to be removed by surgery (inoperable), BRAF V600E or BRAF V600K type | EA6191 / BAMM2 |
| Skin | Melanoma, metastatic (advanced) | EA6192 / PET-Stop |
| Skin | Melanoma, able to be removed by surgery (operable) | EA6194 |
| Throat | Squamous cell oropharyngeal carcinoma, HPV positive type | EA3161 |
| Upper Urinary Tract | High grade (aggressive) | EA8192 |